FDA Expands EVO ICL Age Range to 21-60, Accelerating Shift from Laser Vision Correction

Event summary

  • FDA approves expanded age indication for STAAR Surgical's EVO ICL, now covering patients 21-60 years old (previously 21-45).
  • Three-year clinical trial data shows strong safety profile with no reported cases of pupillary block or pigment dispersion.
  • Laser-based refractive procedures in the U.S. have declined nearly 40% over the past three years.
  • EVO ICL was the most-performed refractive procedure (72%) in patients with -8.0 diopters and above across 19 U.S. practices.

The big picture

The FDA's expanded age indication for the EVO ICL comes as the U.S. refractive vision correction market undergoes a significant shift away from laser-based procedures. With laser procedures declining nearly 40% over the past three years, STAAR Surgical is positioning its EVO ICL as the preferred solution, particularly for patients with high myopia. The long-term safety data and broader age range approval reinforce the company's strategic pivot towards a lens-based approach, potentially reshaping the treatment paradigm for myopia.

What we're watching

Market Adoption
The pace at which surgeons and patients adopt the EVO ICL for broader age ranges and higher myopia cases.
Competitive Dynamics
How STAAR Surgical will leverage this approval to gain market share against laser-based vision correction alternatives.
Regulatory Expansion
Whether the FDA approval will pave the way for similar expansions in other regulatory markets.